An interventional study of Taxifolin and Ergothioneine in Antioxidative Stress, Cold and Influenza, sponsored by University of Southampton. Active, not recruiting at 1 site in United Kingdom. Open to participants aged 50 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-13.
Sponsored by University of Southampton · Not applicable, Interventional, and Basic science
The complexities of the immune system make measuring the impact of dietary interventions upon its function challenging. The immune system is highly responsive to environmental influences, including the diet. An individual's diet provides the energy required to mount a strong and protective immune response, the building blocks required for synthesis of immune mediators such as antibodies and cytokines, and can also indirectly affect immune function via changes in the gut microbiome. Immune function varies across the lifecourse, with a well understood decline in immune function with age, resulting in impaired vaccination responses and an increased risk of infections and of severe complications and mortality arising from common communicable diseases such as influenza. This impaired immunity with ageing is known as immunosenescence and this affects both innate and acquired arms of the immune system.
Expert guidance is available to inform the design of human nutrition trials to ensure they include the most relevant immunological outcomes (Albers, 2013). In this study, ex vivo phagocytosis and oxidative burst of immune cells will be the primary outcome, supported by other ex vivo immune measures of high clinical relevance including functional assessment of cytokine production and expression of activation markers.
Human nutritional trials frequently omit to monitor the degree of immunosenescence in participants, even amongst studies conducted amongst older adults. For example, a recent review of pre- and probiotic trials which assessed immune responses in older adults identified that only two of thirty-six studies assessed any marker of immunosenescence (Childs \& Calder, 2017).
Taxifolin/DHQ is a naturally occurring polyphenol found in apples, onions and other fruits and bark extracts. Ergothioneine is an amino acid found in mushrooms, oats and some bean varieties. We hypothesise that Taxifolin/DHQ and/or Ergothioneine will alter immune function via their established antioxidant effects, and that the effects observed will vary between older adults relative to their degree of immunosenescence.
Though current dietary guidelines advise consumption of 5 portions of fruits and vegetables per day, recent surveys reveal that fewer than 30% of adults achieve this. Antioxidants found within fruits and vegetables are understood to be one of the important aspects by which our diet can influence health. It is important to investigate the effects of such antioxidants through well designed and conducted human trials.
219 studies on the registry are indexed under Common Cold; 23 are open to participants now.
This study's enrollment of 90 is below the median of 150 across 184 interventional studies indexed under Common Cold.
Browse Common Cold studies →University of Southampton is the lead sponsor of 122 studies on the registry; 18 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
250mg/day Taxifolin (also known as Dihydroquercetin). One capsule in the morning for 8 weeks.
Dietary Supplement: Taxifolin
80mg/day Ergothioneine. One capsule in the morning for 8 weeks.
Dietary Supplement: Ergothioneine
One capsule in the morning for 8 weeks.
Dietary Supplement: Control
A naturally occurring polyphenol found in apples, onions and other fruits and bark extracts.
Also known as: Dihydroquercetin
An amino acid found in mushrooms, oats and some bean varieties.
Microcrystalline cellulose.
Phagocytosis activity by granulocytes ex vivo
Mean fluorescence intensity per cell will be assessed by flow cytometry.
Time frame: 8 weeks post intervention
Percentage phagocytosis by monocytes ex vivo
Percentage of cells undergoing phagocytosis will be assessed by flow cytometry.
Time frame: 4 weeks, 8 weeks, 3 months post intervention
Phagocytosis activity by monocytes ex vivo
Mean fluorescence intensity per cell will be assessed by flow cytometry.
Time frame: 4 weeks, 8 weeks, 3 months post intervention
Percentage phagocytosis by granulocytes ex vivo
Percentage of cells undergoing phagocytosis will be assessed by flow cytometry.
Time frame: 4 weeks, 8 weeks, 3 months post intervention
Phagocytosis activity by granulocytes ex vivo
Mean fluorescence intensity per cell will be assessed by flow cytometry.
Time frame: 4 weeks, 3 months post intervention
Percentage oxidative burst by monocytes ex vivo
Percentage of cells undergoing oxidative burst will be assessed by flow cytometry.
Time frame: 4 weeks, 8 weeks, 3 months post intervention
Oxidative burst activity by monocytes ex vivo
Mean fluorescence intensity per cell will be assessed by flow cytometry.
Time frame: 4 weeks, 8 weeks, 3 months post intervention
Percentage oxidative burst by granulocytes ex vivo
Percentage of cells undergoing oxidative burst will be assessed by flow cytometry.
Time frame: 4 weeks, 8 weeks, 3 months post intervention
Oxidative burst activity by granulocytes ex vivo
Mean fluorescence intensity per cell will be assessed by flow cytometry.
Time frame: 4 weeks, 8 weeks, 3 months post intervention
Frequencies of naive T cells
The proportion of naive T cells will be assessed by flow cytometry.
Time frame: 8 weeks
Frequencies of memory T cells
The proportion of memory T cells will be assessed by flow cytometry.
Time frame: 8 weeks
CD57 expression upon T cells.
The proportion of T cells expressing CD57 (a marker associated with chronic immune activation) and the mean fluorescence intensity per cell will be assessed by flow cytometry.
Time frame: 8 weeks
CD28 expression upon T cells.
The proportion of T cells expressing CD28 (a cell surface marker required for T cell activation and survival) and the mean fluorescence intensity per cell will be assessed by flow cytometry.
Time frame: 8 weeks
Plasma lipid peroxides
Participant plasma lipid peroxides will be measured by colorimetric analysis.
Time frame: 8 weeks
Urinary isoprostanes
Participant urinary isoprostanes will be measured by commercially available ELISA.
Time frame: 4 weeks, 8 weeks, 3 months post intervention
Plasma isoprostanes
Participant plasma isoprostanes will be measured by commercially available ELISA.
Time frame: 4 weeks, 8 weeks, 3 months post intervention
Cytokine production by cryopreserved peripheral blood mononuclear cells in response to lipopolyssaccharide
A panel of pro- and anti-inflammatory cytokines secreted by immune cells ex vivo will be assessed by Luminex array.
Time frame: 4 weeks, 8 weeks
Cytokine production by cryopreserved peripheral blood mononuclear cells in response to influenza or coronavirus vaccine products
A panel of pro- and anti-inflammatory cytokines secreted by immune cells ex vivo will be assessed by Luminex array.
Time frame: 4 weeks, 8 weeks
Metabolomic analysis of urine samples
Full metabolic profiling of first-morning urine samples will be used to assess changes to metabolic activity of participants and their microbiome.
Time frame: 4 weeks, 8 weeks, 3 months post intervention
Metabolomic analysis of serum samples
Full metabolic profiling of serum samples will be used to assess changes to metabolic activity of participants.
Time frame: 4 weeks, 8 weeks, 3 months post intervention
Faecal microbiome analysis
Sequences of ribosomal RNA (rRNA) in participant faecal samples will be measured to assess changes in the numbers or proportions of bacterial genera and species/strains.
Time frame: 4 weeks, 8 weeks, 3 months post intervention
Incidence of self-reported seasonal cold, coronavirus and influenza-like illness.
A daily online form will be completed by participants to log any seasonal cold, coronavirus and influenza-like illness.
Time frame: 4 weeks, 8 weeks, 3 months post intervention
Duration of self-reported illness.
A daily online form will be completed by participants to log any self-reported illness.
Time frame: 4 weeks, 8 weeks, 3 months post intervention
Severity of self-reported illness.
A daily online form will be completed by participants to log any self-reported illness.
Time frame: 4 weeks, 8 weeks, 3 months post intervention
Self-reported medication use.
A daily online form will be completed by participants to log any medication use.
Time frame: 4 weeks, 8 weeks, 3 months post intervention
Plan to share: No
Ran from Nov 2021 to primary completion in Sep 2022, 10 months.
Of 49 interventional studies with no phase under Common Cold, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 16. This study's 10 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ergothioneine